ACADIA Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
ACADIA Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 26.6% bzw. 9.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.5% betragen.
Wichtige Informationen
26.6%
Wachstumsrate der Gewinne
24.3%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 28.4% |
| Wachstumsrate der Einnahmen | 9.1% |
| Zukünftige Eigenkapitalrendite | 19.5% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 21 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,150 | 205 | 203 | 268 | 15 |
| 12/31/2025 | 1,050 | 139 | 162 | 234 | 19 |
| 12/31/2024 | 978 | 123 | 157 | 255 | 20 |
| 9/30/2024 | 929 | 129 | 203 | 203 | N/A |
| 6/30/2024 | 891 | 31 | 80 | 81 | N/A |
| 3/31/2024 | 814 | -2 | 24 | 64 | N/A |
| 12/31/2023 | 726 | -61 | -23 | 17 | N/A |
| 9/30/2023 | 632 | -149 | -133 | -93 | N/A |
| 6/30/2023 | 551 | -111 | -74 | -34 | N/A |
| 3/31/2023 | 520 | -146 | -56 | -56 | N/A |
| 12/31/2022 | 517 | -216 | -114 | -114 | N/A |
| 9/30/2022 | 512 | -217 | -113 | -113 | N/A |
| 6/30/2022 | 512 | -205 | -130 | -130 | N/A |
| 3/31/2022 | 493 | -214 | -142 | -142 | N/A |
| 12/31/2021 | 484 | -168 | -127 | -126 | N/A |
| 9/30/2021 | 474 | -192 | -133 | -130 | N/A |
| 6/30/2021 | 463 | -262 | -141 | -136 | N/A |
| 3/31/2021 | 458 | -260 | -155 | -147 | N/A |
| 12/31/2020 | 442 | -282 | -144 | -136 | N/A |
| 9/30/2020 | 419 | -268 | -144 | -138 | N/A |
| 6/30/2020 | 393 | -225 | -139 | -134 | N/A |
| 3/31/2020 | 366 | -238 | -137 | -136 | N/A |
| 12/31/2019 | 339 | -235 | -152 | -151 | N/A |
| 9/30/2019 | 300 | -248 | -162 | -161 | N/A |
| 6/30/2019 | 264 | -268 | -186 | -184 | N/A |
| 3/31/2019 | 238 | -276 | -189 | -186 | N/A |
| 12/31/2018 | 224 | -245 | -170 | -167 | N/A |
| 9/30/2018 | 208 | -249 | -160 | -158 | N/A |
| 6/30/2018 | 185 | -252 | N/A | -174 | N/A |
| 3/31/2018 | 158 | -256 | N/A | -192 | N/A |
| 12/31/2017 | 125 | -289 | N/A | -218 | N/A |
| 9/30/2017 | 93 | -299 | N/A | -251 | N/A |
| 6/30/2017 | 63 | -306 | N/A | -242 | N/A |
| 3/31/2017 | 33 | -309 | N/A | -240 | N/A |
| 12/31/2016 | 17 | -271 | N/A | -208 | N/A |
| 9/30/2016 | 5 | -238 | N/A | -182 | N/A |
| 6/30/2016 | 0 | -206 | N/A | -165 | N/A |
| 3/31/2016 | 0 | -174 | N/A | -138 | N/A |
| 12/31/2015 | 0 | -164 | N/A | -122 | N/A |
| 9/30/2015 | 0 | -147 | N/A | -105 | N/A |
| 6/30/2015 | 0 | -133 | N/A | -91 | N/A |
| 3/31/2015 | 0 | -115 | N/A | -78 | N/A |
| 12/31/2014 | 0 | -92 | N/A | -66 | N/A |
| 9/30/2014 | 0 | -76 | N/A | -59 | N/A |
| 6/30/2014 | 0 | -62 | N/A | -51 | N/A |
| 3/31/2014 | 1 | -50 | N/A | -39 | N/A |
| 12/31/2013 | 1 | -38 | N/A | -32 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ACADDas prognostizierte Gewinnwachstum (26.6% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: ACADDie Erträge des Unternehmens (26.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: ACADEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: ACADDie Einnahmen des Unternehmens (9.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: ACADDie Einnahmen des Unternehmens (9.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ACADDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.5%).